Cathepsin D degrader 1

Anti-hepatic fibrosis agent 3 是一种靶向 Cathepsin D 的口服活性抗肝纤维化化合物,对 COL1A1-promoter 的 IC50 为 53.18 μM,与 Cathepsin D 结合的 Kd 为 8.86 μM,可直接结合并促进 Cathepsin D 的降解,对 Cathepsin B 或 Cathepsin L 无显著作用,同时可抑制肝星状细胞活化、减少细胞外基质沉积及炎症细胞因子的表达,并在大鼠 BDL 和小鼠 CDAHFD 诱导的肝纤维化模型中表现出显著的抗纤维化活性,可用于肝纤维化的研究。
产品编号: MS-D78665 CAS No.: 3127060-85-6 分子式: C22H28N2O3 分子量: 368.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Anti-hepatic fibrosis agent 3 是一种靶向 Cathepsin D 的口服活性抗肝纤维化化合物,对 COL1A1-promoter 的 IC50 为 53.18 μM,与 Cathepsin D 结合的 Kd 为 8.86 μM,可直接结合并促进 Cathepsin D 的降解,对 Cathepsin B 或 Cathepsin L 无显著作用,同时可抑制肝星状细胞活化、减少细胞外基质沉积及炎症细胞因子的表达,并在大鼠 BDL 和小鼠 CDAHFD 诱导的肝纤维化模型中表现出显著的抗纤维化活性,可用于肝纤维化的研究。

生物实验数据

生物活性 Anti-hepatic fibrosis agent 3 is an orally active anti-hepatic fibrosis compound targeting Cathepsin D, with an IC50 of 53.18 μM against the COL1A1 promoter and a Kd of 8.86 μM for Cathepsin D binding; it directly binds to and promotes the degradation of Cathepsin D without significant effects on Cathepsin B or Cathepsin L, inhibits hepatic stellate cell activation, reduces extracellular matrix deposition and inflammatory cytokine expression, exhibits significant anti-fibrotic activity in rat BDL- and mouse CDAHFD-induced liver fibrosis models, and can be used for the study of liver fibrosis.
IC50 & Target

Cathepsin D

8.86 μM (Kd)

体外研究
(In Vitro)

Anti-hepatic fibrosis agent 3 (compound 9a) 可强效抑制 LX-2 细胞中 COL1A1 启动子的活性,其 IC50 为 53.18 μM,选择性指数为 3.60。
Anti-hepatic fibrosis agent 3 (20-80 μM; 24 h) 可抑制 TGFβ1 诱导的 LX-2 细胞中纤维化标志物蛋白 (COL1A1、纤连蛋白、α-SMA、p-Smad2) 的表达,并下调纤维化相关基因的 mRNA 水平 (COL1A1、纤连蛋白、TGFB1、MMP2、ACTA2、TIMP1),且以浓度依赖的方式降低小鼠肝星状细胞 (mHSC) 中纤维化相关蛋白的表达。
Anti-hepatic fibrosis agent 3 (20-80 μM; 24 h) 可呈剂量依赖性下调 LX-2 和 mHSC 细胞中 pro-Cathepsin D 与 Cathepsin D 的蛋白水平,但对 Cathepsin B 和 Cathepsin L 无影响;同时可降低经 Lipopolysaccharides (MS-X54539) 刺激的 LX-2 和 mHSC 细胞中炎症蛋白 (IL-1β、caspase-1) 的表达。
Anti-hepatic fibrosis agent 3 (80 μM; 6-48 h) 可加速经 Cycloheximide (MS-C76056) 预处理的 LX-2 细胞中前组织蛋白酶 D 和组织蛋白酶 D 的降解。

RT-PCR

Cell Line: LX-2 cells
Concentration: 20 μM, 40 μM, 80 μM
Incubation Time: 24 h
Result: Dose-dependently downregulates the mRNA levels of fibrosis-related genes (COL1A1, fibronectin, TGFB1, MMP2, ACTA2, TIMP1).

Western Blot Analysis

Cell Line: Cycloheximide (CHX)-pretreated LX-2 cells
Concentration: 80 μM
Incubation Time: 6 h, 12 h, 24 h, 36 h, 48 h
Result: Significantly accelerated the degradation of pro-Cathepsin D and Cathepsin D.

Western Blot Analysis

Cell Line: LPS-stimulated LX-2 cells, LPS-stimulated mHSC
Concentration: 20 μM, 40 μM, 80 μM
Incubation Time: 24 h
Result: Significantly decreased the protein levels of inflammatory factors IL-1β and caspase-1.

Western Blot Analysis

Cell Line: LX-2 cells, mouse hepatic stellate cells (mHSC)
Concentration: 20 μM, 40 μM, 80 μM
Incubation Time: 24 h
Result: Dose-dependently downregulated the protein levels of Cathepsin D, pro-Cathepsin D, COL1A1, fibronectin, α-SMA and p-Smad2, and showed no significant effect on Cathepsin B and Cathepsin L.

Western Blot Analysis

Cell Line: TGFβ1-stimulated LX-2 cells
Concentration: Anti-hepatic fibrosis agent 3 (20 μM, 40 μM, 80 μM), L-theanine (20 μM, 40 μM, 80 μM)
Incubation Time: 24 h
Result: Dose-dependently downregulates fibrosis-related proteins (COL1A1, fibronectin, α-SMA, p-Smad2, MMP2, TGFβ1, CTGF, TIMP1); exhibits stronger inhibitory activity than L-theanine and most tested analogs.
体内研究
(In Vivo)

Anti-hepatic fibrosis agent 3 (100-200 mg/kg; p.o.; daily; 14 days) 可剂量依赖性地缓解雄性 Sprague-Dawley 大鼠中 BDL 诱导的肝纤维化与炎症,在 100 mg/kg 和 200 mg/kg 剂量下可显著降低血清肝损伤标志物水平、胶原沉积量、纤维化及炎症生物标志物的表达量,以及 Cathepsin D 水平。
Anti-hepatic fibrosis agent 3 (100-200 mg/kg; p.o.; daily; 4 weeks) 可剂量依赖性地改善 C57BL/6 小鼠中由 CDAHFD 诱导的代谢性肝纤维化与炎症;在 100 mg/kg 和 200 mg/kg 剂量下,其可显著改善血清肝损伤标志物水平、减少胶原沉积、降低纤维化及炎症生物标志物的表达,并下调组织蛋白酶 D 水平。

Animal Model: Sprague-Dawley (male, 180-200 g, BDL surgery-induced hepatic fibrosis)
Dosage: 100 mg/kg; 200 mg/kg
Administration: p.o.; daily; 14 days
Result: Significantly reduced serum levels of aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and total bilirubin (TBIL) in a dose-dependent manner.
Improved liver elasticity and surface smoothness compared to BDL model group.
Reduced liver injury and collagen deposition in a dose-dependent manner via histological analysis; significantly reduced hepatic necrosis at 200 mg/kg dose.
Significantly reduced liver hydroxyproline content in 200 mg/kg dose group.
Downregulated protein levels of fibrotic biomarkers (Fibronectin, COL1A1, α-SMA, TGFβ1, CTGF, TIMP1) in liver tissue in a dose-dependent manner.
Downregulated mRNA levels of Col1a1 and Acta2 in 200 mg/kg dose group.
Reduced protein levels of pro-Cathepsin D and Cathepsin D in liver tissue in a dose-dependent manner.
Inhibited protein and mRNA expression of pro-inflammatory factors (IL-6, IL-1β) and reduced inflammation score in pathological sections in a dose-dependent manner.
Animal Model: C57BL/6 (8-week-old, CDAHFD feeding-induced hepatic fibrosis)
Dosage: 100 mg/kg; 200 mg/kg
Administration: p.o.; daily; 4 weeks
Result: Improved serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBIL) in a dose-dependent manner, with greater efficacy than positive control OCA for ALT and ALP.
Partially restored hepatic luster and elasticity compared to CDAHFD model group.
Reduced hepatic ballooning degeneration and collagen deposition via histological analysis; reduced hepatic fibrosis scores in a dose-dependent manner via semiquantitative scoring.
Significantly reduced liver hydroxyproline content in both dose groups.
Downregulated protein levels of fibrotic biomarkers (COL1A1, Fibronectin, α-SMA) and mRNA levels of Col1a1, Mmp2, Timp1, and Acta2 in liver tissue.
Reduced protein levels of pro-Cathepsin D and Cathepsin D in liver tissue in a dose-dependent manner.
Inhibited protein and mRNA expression of pro-inflammatory factor (IL-6) in a dose-dependent manner.

化学信息

分子量 368.47
分子式 C22H28N2O3
CAS No. 3127060-85-6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础